JPH07506594A - 抗転移剤として有用な生物学的に活性なウレイド誘導体 - Google Patents

抗転移剤として有用な生物学的に活性なウレイド誘導体

Info

Publication number
JPH07506594A
JPH07506594A JP6519502A JP51950294A JPH07506594A JP H07506594 A JPH07506594 A JP H07506594A JP 6519502 A JP6519502 A JP 6519502A JP 51950294 A JP51950294 A JP 51950294A JP H07506594 A JPH07506594 A JP H07506594A
Authority
JP
Japan
Prior art keywords
methyl
bis
pyrrole
imino
carbonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP6519502A
Other languages
English (en)
Japanese (ja)
Inventor
モンジエーリ，ニコラ
ビアソリ，ジヨバンニ
マリアーニ，マリアンジエラ
ソラ，フランチエスコ
Original Assignee
フアルマシア・エ・アツプジヨン・エツセ・ピー・アー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フアルマシア・エ・アツプジヨン・エツセ・ピー・アー filed Critical フアルマシア・エ・アツプジヨン・エツセ・ピー・アー
Publication of JPH07506594A publication Critical patent/JPH07506594A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP6519502A 1993-03-05 1994-01-31 抗転移剤として有用な生物学的に活性なウレイド誘導体 Pending JPH07506594A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB939304589A GB9304589D0 (en) 1993-03-05 1993-03-05 Biologically active ureido derivatives useful as antimetastic agents
GB9304589.6 1993-03-05
PCT/EP1994/000268 WO1994020095A1 (en) 1993-03-05 1994-01-31 Biologically active ureido derivatives useful as antimetastatic agents

Publications (1)

Publication Number Publication Date
JPH07506594A true JPH07506594A (ja) 1995-07-20

Family

ID=10731580

Family Applications (1)

Application Number Title Priority Date Filing Date
JP6519502A Pending JPH07506594A (ja) 1993-03-05 1994-01-31 抗転移剤として有用な生物学的に活性なウレイド誘導体

Country Status (17)

Country Link
US (1) US5534539A (en, 2012)
EP (1) EP0639073A1 (en, 2012)
JP (1) JPH07506594A (en, 2012)
KR (1) KR950701217A (en, 2012)
CN (1) CN1103533A (en, 2012)
AU (1) AU669269B2 (en, 2012)
CA (1) CA2134098A1 (en, 2012)
FI (1) FI945164A7 (en, 2012)
GB (1) GB9304589D0 (en, 2012)
HU (1) HUT71400A (en, 2012)
IL (1) IL108665A (en, 2012)
MY (1) MY110004A (en, 2012)
NZ (1) NZ261308A (en, 2012)
PL (1) PL305981A1 (en, 2012)
TW (1) TW262465B (en, 2012)
WO (1) WO1994020095A1 (en, 2012)
ZA (1) ZA941126B (en, 2012)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9403909D0 (en) * 1994-03-01 1994-04-20 Erba Carlo Spa Ureido derivatives of naphthalenephosphonic acids and process for their preparation
GB9504065D0 (en) * 1995-03-01 1995-04-19 Pharmacia Spa Poly-pyrrolecarboxamidonaphthalenic acid derivatives
GB9602721D0 (en) * 1996-02-09 1996-04-10 Pharmacia Spa Biologically active ureido derivatives useful in the treatment of multiple sclerosis
WO1999027939A1 (en) 1997-12-04 1999-06-10 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Ureido derivatives of poly-4-amino-2-carboxy-1-methyl pyrrole compounds for inhibition of inflammation
GB9727524D0 (en) * 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Synergistic antitumor composition containing a biologically active ureido compound
WO1999058126A1 (en) * 1998-05-11 1999-11-18 The Endowment For Research In Human Biology, Inc. Use of neomycin for treating angiogenesis-related diseases
KR20080035702A (ko) * 2002-01-11 2008-04-23 상꾜 가부시키가이샤 아미노 알코올 유도체 또는 포스폰산 유도체 및 이들을함유하는 의약 조성물
CN1921847B (zh) 2004-02-24 2010-06-16 三共株式会社 氨基醇化合物
EP3381897A1 (en) 2017-03-27 2018-10-03 Leadiant Biosciences SA Derivatives of the disodium 2,2'-{carbonylbis[imino-3,1-phenylenecarbonylimino(1-methyl-1h-pyrrole-4,2-diyl)carbonylimino]}dinaphthalene-1,5-disulfonate salt and related compounds as heparanase inhibitors for the treatment of cancer
CN107235866B (zh) 2017-06-13 2019-09-10 重庆医科大学 一种用于检测次磺酸化蛋白质的荧光探针、制备方法及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986002266A1 (en) * 1984-10-12 1986-04-24 United States Of America, Represented By The Unite Use of suramin for clinical treatment of infection with any of the members of the family of human t-cell leukemia (htlv) viruses including lymphadenopathy virus (lav)
CA1308516C (en) * 1987-07-06 1992-10-06 J. William Lown Oligopeptide anticancer and antiviral agents
GB9000644D0 (en) * 1990-01-11 1990-03-14 Erba Carlo Spa New ureido derivatives of poly-4-amino-2-carboxy-1-methyl compounds
GB9024738D0 (en) * 1990-11-14 1991-01-02 Erba Carlo Spa A new method of treatment of tumor necroisis factor(tnf)-related diseases
GB9116896D0 (en) * 1991-08-06 1991-09-18 Erba Carlo Spa 3-deoxymannosamine derivatives and process for their preparation
GB9216962D0 (en) * 1992-08-11 1992-09-23 Erba Carlo Spa Therapeutically active naphthalenesulfonic-pyrrolecarboxamido derivatives

Also Published As

Publication number Publication date
CA2134098A1 (en) 1994-09-15
FI945164A0 (fi) 1994-11-02
MY110004A (en) 1997-11-29
ZA941126B (en) 1994-08-30
HUT71400A (en) 1995-11-28
IL108665A (en) 1997-03-18
IL108665A0 (en) 1994-05-30
NZ261308A (en) 1996-02-27
AU669269B2 (en) 1996-05-30
KR950701217A (ko) 1995-03-23
US5534539A (en) 1996-07-09
WO1994020095A1 (en) 1994-09-15
CN1103533A (zh) 1995-06-07
EP0639073A1 (en) 1995-02-22
GB9304589D0 (en) 1993-04-21
AU6000394A (en) 1994-09-26
TW262465B (en, 2012) 1995-11-11
FI945164A7 (fi) 1994-11-02
PL305981A1 (en) 1995-02-20

Similar Documents

Publication Publication Date Title
JP3121343B2 (ja) ポリ―４―アミノ―２―カルボキシ―１―メチル化合物の新規ウレイド誘導体
CN110418796A (zh) 托法替尼(tofacitinib)的葡萄糖苷酸前药
JP2001504109A (ja) ベンゾ複素環ジスタマイシン誘導体、それらを製造する方法および抗腫瘍および抗ウイルス剤としてのそれらの用途
WO2019050850A1 (en) BIGUANIDINE DERIVATIVES OF THERAPEUTIC AGENTS, AND PREPARATION METHODS AND METHODS OF USING SAME
JPH07506594A (ja) 抗転移剤として有用な生物学的に活性なウレイド誘導体
CN115518065B (zh) 一种咪唑类衍生物在制备抗肿瘤药物组合物中的应用
KR101565430B1 (ko) N-메틸렌나프토[2,1-b]퓨란-2-카보하이드라지드 유도체를 유효성분으로 포함하는 암 예방 또는 치료용 조성물
JPH10506410A (ja) 抗腫瘍剤及び抗ウイルス剤としてのビス−（２−ハロエチル）アミノフェニル置換ジスタマイシン誘導体
WO2007121662A1 (fr) Dérivés de diphénylurée utilisés comme inhibiteurs de kinase, compositions et utilisations de ceux-ci
KR20200123184A (ko) 증식이상 장애를 치료하기 위한 물질 및 방법
CN111925318A (zh) 一个烟醇醚衍生物的马来酸盐及其晶型和应用
AU670194B2 (en) Biologically active ureido derivatives useful in the treatment of lentivirus-induced disease
JPH06184098A (ja) 治療上有効なナフタレンスルホン系ピロールカルボキサミド誘導体
BRPI0611096A2 (pt) (5z)-5-(6-quinoxalinilmetilideno)-2-[(2,6-diclorofenil)a mino]-1,3-tiazol-4(5h)-ona
KR20190090729A (ko) 토파시티닙의 신규 염, 이의 제조방법 및 이를 포함하는 약학 조성물
JPH02129181A (ja) １−アリール−４−（１ｈ−イミダゾール−１−イル）フタラジン誘導体
HK1006455B (en) Ureido derivatives of poly-4-amino-2-carboxy-1-methyl compounds
JPH02134319A (ja) イソオキサゾール化合物を含有する脳機能改善剤
MXPA99011996A (en) Bis-indole derivatives having antimetastatic activity, a process for their preparation and pharmaceutical compositions containing them